[Therapeutic aims for atrial fibrillation in patients with heart failure].
Lewalter
T
T
Abteilung für Kardiologie, St. Vincenz-Krankenhaus GmbH, Am Busdorf 2, 33098 Paderborn. t.lewalter@vincenz.de
Nitschmann
S
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000401:mortality; D003131:Combined Modality Therapy; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004554:Electric Countershock; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006339:Heart Rate; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018487:Ventricular Dysfunction, Left
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D000638:Amiodarone